Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arca Biopharma (ABIO) has provided an update.
ARCA biopharma, Inc. has announced the mutual decision to end Dr. Michael Bristow’s role as President, CEO, and Director, effective April 3, 2024, with no disputes cited. He will receive a severance payment and has also agreed to a consulting deal with ARCA. Simultaneously, Thomas A. Keuer, long-serving COO, steps up as President and principal executive officer, without extra pay, until the completion of ARCA’s merger with Oruka Therapeutics. Keuer’s background and lack of material interest in transactions are detailed in ARCA’s regulatory filings.
For an in-depth examination of ABIO stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money